Showing results (291-300 of 380) with videos related to
Sort By:
Pageof 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabBenjamin Weide, Alexander Martens, Jessica C Hassel, et al.European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumorsFlorentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.Oncotarget|October 23, 2018
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter studyJulia K Tietze, Andrea Forschner, Carmen Loquai, et al.Journal for Immunotherapy of Cancer|January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 studyJason Chesney, Karl D Lewis, Harriet Kluger, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.Journal of Translational Medicine|October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabDomenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.The New England Journal of Medicine|October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.Journal for Immunotherapy of Cancer|October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.Pageof 38